Sientra’s (SIEN) Buy Rating Reaffirmed at Canaccord Genuity
Canaccord Genuity restated their buy rating on shares of Sientra (NASDAQ:SIEN) in a research note released on Friday. The firm currently has a $19.00 price objective on the medical instruments supplier’s stock.
SIEN has been the subject of a number of other reports. Stifel Nicolaus reiterated a hold rating and set a $14.00 target price (up from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. BidaskClub upgraded Sientra from a sell rating to a hold rating in a research report on Friday, December 15th. Zacks Investment Research upgraded Sientra from a sell rating to a hold rating in a research report on Tuesday. ValuEngine upgraded Sientra from a sell rating to a hold rating in a research report on Sunday, December 31st. Finally, William Blair upgraded Sientra from a market perform rating to an outperform rating in a research report on Wednesday, September 13th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $15.00.
Sientra (NASDAQ:SIEN) opened at $13.49 on Friday. Sientra has a 52 week low of $7.20 and a 52 week high of $16.68. The company has a quick ratio of 1.92, a current ratio of 2.87 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $266.68, a P/E ratio of -4.73 and a beta of -1.47.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.06). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The business had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. During the same quarter in the previous year, the company earned ($0.55) earnings per share. The company’s revenue for the quarter was up 50.8% compared to the same quarter last year. equities analysts anticipate that Sientra will post -3.23 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pura Vida Investments LLC bought a new position in shares of Sientra during the 3rd quarter valued at approximately $2,892,000. Bamco Inc. NY lifted its position in Sientra by 6.4% in the third quarter. Bamco Inc. NY now owns 501,500 shares of the medical instruments supplier’s stock worth $7,723,000 after buying an additional 30,000 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in Sientra in the third quarter worth $1,098,000. Wells Fargo & Company MN lifted its position in Sientra by 175.2% in the third quarter. Wells Fargo & Company MN now owns 22,903 shares of the medical instruments supplier’s stock worth $353,000 after buying an additional 14,582 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in Sientra by 1.1% in the third quarter. Schroder Investment Management Group now owns 437,276 shares of the medical instruments supplier’s stock worth $6,730,000 after buying an additional 4,815 shares during the last quarter. Hedge funds and other institutional investors own 76.63% of the company’s stock.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.